Munther A. Khamashta

Munther A. Khamashta's AcademicInfluence.com Rankings

Medical

#1256

World Rank

#1576

Historical Rank

Rheumatology

World Rank

Historical Rank

medical Degrees

Munther A. Khamashta

Biology

#5338

World Rank

#7795

Historical Rank

Immunology

#247

World Rank

#257

Historical Rank

Neuroscience

#587

World Rank

#613

Historical Rank

biology Degrees

Download Badge

Medical
Biology

Munther A. Khamashta's Degrees

Doctorate Medicine University of Baghdad

Why Is Munther A. Khamashta Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Munther A. Khamashta's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. (2011) (3649)
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. (1999) (2685)
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. (2002) (1813)
Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients (2003) (1214)
The management of thrombosis in the antiphospholipid-antibody syndrome. (1995) (1073)
The “Primary” Antiphospholipid Syndrome: Major Clinical and Serological Features (1989) (998)
Adult haemophagocytic syndrome (2014) (938)
Systemic Lupus Erythematosus: Clinical and Immunologic Patterns of Disease Expression in a Cohort of 1,000 Patients (1993) (909)
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines (2003) (743)
The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation (2016) (714)
Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases (2007) (696)
Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus (2017) (585)
Systemic lupus erythematosus (2001) (578)
Anti-inflammatory and immunosuppressive drugs and reproduction (2006) (548)
EULAR recommendations for the management of antiphospholipid syndrome in adults (2019) (511)
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome (2015) (509)
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies (2013) (471)
Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. (1994) (471)
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies (2011) (458)
Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. (2003) (457)
Morbidity and mortality in systemic lupus erythematosus during a 5-year period - A multicenter prospective study of 1,000 patients (1999) (389)
Antiphospholipid antibodies (1994) (382)
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (2014) (377)
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study (2016) (371)
Immune-related adverse events of checkpoint inhibitors (2020) (360)
Maternal Use of Hydroxychloroquine Is Associated With a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody–Associated Cardiac Manifestations of Neonatal Lupus (2012) (353)
BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. (2016) (341)
Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. (1989) (328)
Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. (1997) (313)
Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus (1990) (309)
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients (2008) (306)
Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. (2000) (306)
Autoimmune diseases induced by TNF-targeted therapies. (2008) (305)
A study of sixty pregnancies in patients with the antiphospholipid syndrome. (1996) (302)
The frequency and outcome of lupus nephritis: results from an international inception cohort study. (2016) (301)
A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. (2007) (293)
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial (2016) (292)
Autoimmune diseases induced by biological agents: a double-edged sword? (2010) (289)
The Role of the Tissue Factor Pathway in the Hypercoagulable State in Patients with the Antiphospholipid Syndrome (1998) (285)
Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. (2001) (251)
Antiphospholipid syndrome (2010) (248)
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. (2009) (243)
Thromboprophylaxis with Low Molecular Weight Heparin (Fragmin) in High Risk Pregnancies (1997) (242)
GAPSS: the Global Anti-Phospholipid Syndrome Score. (2013) (228)
Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. (1990) (227)
Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. (1997) (226)
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults (2018) (226)
Systemic lupus erythematosus and pregnancy. (2006) (225)
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. (2012) (221)
Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients (1998) (214)
Oxidation of LDL and its clinical implication. (2008) (213)
Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus (2004) (196)
Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. (2006) (195)
Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. (2003) (192)
Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. (1996) (192)
The clinical spectrum of autoimmune congenital heart block (2015) (192)
Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome (2013) (188)
Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. (1995) (187)
Glucocorticoid use and abuse in SLE. (2012) (183)
Assessing disease activity in SLE patients during pregnancy (1999) (176)
Seronegative antiphospholipid syndrome (2003) (172)
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus (2010) (167)
Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. (2000) (167)
Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. (2010) (166)
Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. (1994) (166)
Can Neurologic Manifestations of Hughes (Antiphospholipid) Syndrome Be Distinguished from Multiple Sclerosis?: Analysis of 27 Patients and Review of the Literature (2000) (165)
The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. (2015) (164)
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients (2010) (159)
Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome (2010) (157)
Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. (2002) (157)
Central nervous system involvement in the antiphospholipid (Hughes) syndrome. (2003) (155)
Acute Viral Infections in Patients With Systemic Lupus Erythematosus: Description of 23 Cases and Review of the Literature (2008) (154)
Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. (1996) (152)
First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. (2011) (151)
Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. (2003) (151)
beta 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. (1994) (150)
Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. (2002) (146)
Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. (2004) (145)
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. (2016) (144)
The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. (2004) (135)
Long-Term Follow-Up in 128 Patients With Primary Antiphospholipid Syndrome: Do They Develop Lupus? (2005) (133)
Pregnancy Outcomes in Systemic Lupus Erythematosus with and without Previous Nephritis (2011) (133)
Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. (1993) (132)
Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study (2012) (132)
Treatment of pregnant patients with antiphospholipid syndrome (2003) (131)
Thrombocytopenia in the antiphospholipid syndrome (1997) (128)
Obstetric outcome in systemic lupus erythematosus. (1995) (128)
Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. (1998) (128)
High Prevalence of Significant Heart Valve Lesions in Patients with the 'Primary' Antiphospholipid Syndrome (1991) (127)
Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases. (2015) (125)
BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. (2016) (125)
Numerical scoring for the BILAG-2004 index (2010) (124)
Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. (1998) (123)
Seronegative antiphospholipid syndrome. (2013) (122)
Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. (1988) (122)
Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide (1997) (122)
Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances (2017) (121)
Features associated with epilepsy in the antiphospholipid syndrome. (2004) (121)
Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis (1991) (121)
Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report (2003) (120)
Pregnancy and reproduction in autoimmune rheumatic diseases. (2011) (120)
Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. (2004) (119)
Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. (1998) (119)
Management of the obstetric antiphospholipid syndrome. (2004) (116)
The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review (2014) (114)
Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. (1995) (114)
Calprotectin in Patients with Systemic Lupus Erythematosus: Relation to Clinical and Laboratory Parameters of Disease Activity (1993) (113)
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort (2012) (111)
Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus. (2002) (110)
Antiprothrombin antibodies detected in two different assay systems (2005) (110)
Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. (1997) (109)
Antiphospholipid antibodies and antiphospholipid syndrome (1995) (109)
Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’) (2011) (107)
Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension (2003) (107)
The placental bed in pregnancies complicated by primary antiphospholipid syndrome. (2006) (106)
The BILAG-2004 index is sensitive to change for assessment of SLE disease activity (2009) (104)
GAPSS : the Global AntiPhospholipid Syndrome Score (2013) (102)
Characterization of the endothelial surface proteins recognized by anti-endothelial antibodies in primary and secondary autoimmune vasculitis. (1994) (102)
The efficacy of novel B cell biologics as the future of SLE treatment: a review. (2014) (101)
Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies (2003) (101)
Prophylaxis of the antiphospholipid syndrome: a consensus report (2003) (99)
Pregnancy in systemic lupus erythematosus. (1996) (99)
Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. (1998) (98)
The central nervous system in systemic lupus erythematosus (2004) (98)
British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus (2007) (97)
Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. (2000) (97)
Appearance of systemic lupus erythematosus after thymectomy: four case reports and review of the literature (1995) (96)
Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. (2012) (95)
Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosus. (1996) (94)
The hematologic manifestations of the antiphospholipid syndrome. (2008) (93)
Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome (2006) (93)
Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. (2006) (93)
Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. (2010) (92)
Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. (2006) (90)
Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review (2014) (90)
Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. (2004) (88)
Major histocompatibility complex associations with primary antiphospholipid syndrome. (1992) (88)
Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2014) (87)
Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. (1998) (87)
Mycophenolate mofetil treatment in resistant myositis. (2007) (86)
Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. (1989) (85)
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. (2013) (84)
Chorea in systemic lupus erythematosus: association with antiphospholipid antibodies. (1988) (83)
Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil) (2006) (82)
Myocardial infarction and antiphospholipid antibodies in SLE and related disorders. (1989) (82)
Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. (1998) (80)
Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. (1992) (80)
Lupus and pregnancy: integrating clues from the bench and bedside (2011) (80)
A chimeric antibody with the human γ1 constant region as a putative standard for assays to detect IgG β2‐glycoprotein I–dependent anticardiolipin and anti–β2‐glycoprotein I antibodies (1999) (80)
Patterns of systemic lupus erythematosus expression in Europe. (2014) (79)
Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002 (2003) (79)
Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. (2011) (78)
McMaster RARE‐Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome (2018) (78)
The global anti-phospholipid syndrome score in primary APS. (2015) (77)
Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. (1995) (77)
Release of calreticulin from neutrophils may alter C1q-mediated immune functions. (1997) (76)
The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. (1997) (75)
Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE (2015) (75)
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). (2014) (75)
Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment. (2012) (75)
Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. (2005) (75)
Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale. (2004) (75)
The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy. (2006) (74)
Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus (2014) (74)
Systemic lupus erythematosus. (1977) (73)
The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review. (2013) (72)
Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. (1997) (72)
Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. (1991) (71)
Prednisone in lupus nephritis: how much is enough? (2014) (70)
Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. (2008) (70)
Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort (2014) (69)
Systemic Lupus Erythematosus: Sex Hormones in Male Patients (1993) (68)
Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort (2019) (67)
Review: Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: A myth or an existing entity? (2010) (67)
Migraine and stroke in young women. (2000) (66)
Antiphospholipid syndrome and the kidneys. (2006) (65)
Antiphospohlipid syndrome in obstetrics. (2012) (65)
Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. (1990) (65)
Low dose methotrexate treatment in adult Still's disease. (1992) (65)
Prevalence of the antiphospholipid syndrome in primary systemic vasculitis (2005) (65)
Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study (2018) (65)
Endothelial Cells as a Target for Antiphospholipid Antibodies: Role of Anti‐Beta 2 Glycoprotein I Antibodies (1997) (65)
Central nervous system involvement in systemic lupus erythematosus: Overview on classification criteria. (2013) (64)
Plasma Tumor Necrosis Factor α Levels and the –238* A Promoter Polymorphism in Patients with Antiphospholipid Syndrome (2001) (64)
Prevalence and Clinical Correlations of Antibodies Against Six β2-Glycoprotein-I-Related Peptides in the Antiphospholipid Syndrome (2003) (64)
Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. (1996) (64)
25‐Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort (2014) (63)
Vasculitis induced by tumor necrosis factor-targeted therapies (2008) (63)
Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not! (2009) (63)
Closing the Serological Gap in the Antiphospholipid Syndrome: The Value of “Non-criteria” Antiphospholipid Antibodies (2017) (62)
A Study of 100 High Risk Lupus Pregnancies (1992) (61)
A need for standardization of the anti-endothelial-cell antibody test. (1995) (60)
Management of antiphospholipid syndrome (2018) (59)
The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies (2015) (58)
Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis. (2008) (57)
Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. (2008) (57)
Prevalence and associations of an abnormal ankle-brachial index in systemic lupus erythematosus: a pilot study (2003) (57)
Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. (2010) (55)
Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment (2014) (55)
Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. (1998) (55)
Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data (2004) (55)
Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant (2012) (55)
ACP Broadsheet no 136: February 1993. Detection and importance of anticardiolipin antibodies. (1993) (53)
Laboratory diagnosis and management challenges in the antiphospholipid syndrome (2006) (53)
Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. (2003) (53)
Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. (2016) (53)
Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). (2019) (52)
Thrombosis and Antiphospholipid Syndrome: a Preliminary Assessment of Three Antithrombotic Treatments (1994) (52)
Hughes syndrome: antiphospholipid antibodies move closer to thrombosis in 1994. (1995) (51)
Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. (2009) (51)
B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. (2013) (51)
HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients. (2001) (51)
Renal involvement in antiphospholipid syndrome (2014) (51)
Atheroma: links with antiphospholipid antibodies, Hughes syndrome and lupus. (1999) (51)
Neuropsychiatric Involvement in Systemic Lupus Erythematosus (2011) (50)
Management of pregnancy in antiphospholipid syndrome. (2001) (50)
Allergic Disorders in Systemic Lupus Erythematosus (1993) (50)
Management of refractory anti-phospholipid syndrome. (2011) (50)
Thrombotic Risk Assessment in Systemic Lupus Erythematosus: Validation of the Global Antiphospholipid Syndrome Score in a Prospective Cohort (2014) (49)
Antibodies to endothelial cells in dermatomyositis: association with interstitial lung disease. (1991) (49)
Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies (2015) (48)
A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies. (1999) (48)
Anti‐endothelial cell antibodies: only for scientists or for clinicians too? (1996) (48)
Development and initial validation of a self‐assessed lupus organ damage instrument (2010) (47)
Pregnancy in granulomatous vasculitis. (1995) (47)
Management of Thrombosis in Antiphospholipid Syndrome and Systemic Lupus Erythematosus in Pregnancy (2005) (47)
Anti-myeloperoxidase autoantibodies in patients with necrotizing glomerular and alveolar capillaritis. (1992) (47)
Nonsteroidal Anti-Inflammatory Drugs and Reversible Female Infertility (2002) (47)
Warfarin and azathioprine: a drug interaction does exist. (1993) (47)
Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus (2018) (47)
Thymulin modulates cytokine release by peripheral blood mononuclear cells: a comparison between healthy volunteers and patients with systemic lupus erythematosus. (1993) (47)
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. (2018) (47)
European Attempts to Set Guidelines for Improving Diagnostics of Autoimmune Rheumatic Disorders (2006) (47)
Placentation, antiphospholipid syndrome and pregnancy outcome (2001) (45)
Antiphospholipid antibodies and HLA associations in primary Sjögren's syndrome. (1992) (45)
Antiphospholipid (Hughes') syndrome (1997) (45)
Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2018) (45)
Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. (2005) (45)
Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. (2016) (45)
Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment (2001) (44)
Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: outcome following anticoagulation. (2005) (44)
Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. (2000) (44)
Antiphospholipid syndrome: linking many specialties. (1989) (43)
Rituximab Therapy in Lupus Nephritis: Current Clinical Evidence (2011) (43)
Association of antiphosphatidylserine/prothrombin autoantibodies with HLA class II genes. (2000) (43)
Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism (2016) (43)
Normal expression of tissue factor, thrombomodulin, and annexin V in placentas from women with antiphospholipid syndrome. (1999) (42)
Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome. (1999) (42)
Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus (2003) (42)
Absence of conduction defects in the electrocardiograms [correction of echocardiograms] of mothers with children with congenital complete heart block. (2001) (42)
Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance (2003) (42)
Contraceptive practices in women with systemic lupus erythematosus and/or antiphospholipid syndrome: What advice should we be giving? (2001) (42)
Clinical, endoscopic, immunologic, and therapeutic aspects of oropharyngeal and esophageal candidiasis in HIV-infected patients: a survey of 114 cases. (1992) (41)
Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome (2014) (41)
Autoantibodies against endothelial cells, extracellular matrix, and human collagen type IV in patients with systemic vasculitis. (1994) (41)
Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome (2016) (41)
Thromboprophylaxis in Antiphospholipid Syndrome Pregnancies with Previous Cerebral Arterial Thrombotic Events: Is Warfarin Preferable? (1998) (41)
Malignancy in Systemic Lupus Erythematosus: a Report of Five Cases in a Series of 96 Patients (1993) (41)
B-cell-depleting therapy in systemic lupus erythematosus. (2012) (41)
Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome (2011) (41)
Splenectomy for refractory thrombocytopenia in the antiphospholipid syndrome. (1999) (40)
Systemic lupus erythematosus in 50 year olds. (1992) (40)
Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future (2010) (40)
HLA-DP genotyping in patients with systemic lupus erythematosus: correlations with autoantibody subsets. (1992) (39)
Up-Regulated Tissue Factor Expression in Antiphospholipid Syndrome (1997) (39)
Cardiac valve replacement in patients with antiphospholipid syndrome (2012) (39)
Lack of cross-reaction between antibodies to beta2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome. (1998) (39)
Pregnancy outcome in patients with systemic vasculitis: a single-centre matched case-control study. (2015) (39)
Numerical scoring for the Classic BILAG index (2009) (38)
Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome (2012) (38)
Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2019) (38)
Headache and memory loss: rapid response to heparin inthe antiphospholipid syndrome (2001) (38)
Atherosclerosis and autoimmunity (2001) (38)
The hepatic complications of the antiphospholipid antibodies. (1991) (37)
Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins. (2004) (37)
Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. (2012) (37)
Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome (2012) (37)
Anti-β2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome (2007) (37)
Antiphospholipid antibodies, systemic lupus erythematosus, and non-traumatic metatarsal fractures (2004) (37)
Anticardiolipin antibodies in patients from Malaysia with systemic lupus erythematosus. (1991) (36)
Determination of autoantibodies to annexin XI in systemic autoimmune diseases (2000) (36)
Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome. (1998) (36)
Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort (2018) (36)
Sticky blood and headache (2001) (36)
Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event (2003) (35)
High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. (2012) (35)
Thrombosis in Churg-Strauss syndrome. Beyond vasculitis? (1996) (35)
Lipoprotein(a) oxidation and autoantibodies: a new path in atherothrombosis (2000) (35)
Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome (2001) (34)
Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. (1999) (34)
10 Years of belimumab experience: What have we learnt? (2021) (34)
Increase in the heart rate-corrected QT interval in children of anti-Ro-positive mothers, with a further increase in those with siblings with congenital heart block: comment on the article by Cimaz et al. (2001) (34)
Prothrombin Mutation Is not Associated with Thrombosis in Patients with Antiphospholipid Syndrome (1998) (34)
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2020) (33)
Antiphospholipid syndrome and renal artery stenosis. (2000) (33)
Isotype profile and clinical relevance of anticardiolipin antibodies in Sjögren's syndrome. (1992) (33)
Antiphospholipid syndrome in pregnancy. (2007) (33)
How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. (2007) (32)
Thymulin and its role in immunomodulation. (1992) (32)
Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol. (2005) (32)
A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach (2016) (32)
Hughes Syndrome: History (2000) (32)
EASI—The European Autoimmunity Standardisation Initiative (2007) (32)
Antiphospholipid antibodies in leprotic patients: a correlation with disease manifestations. (2000) (31)
Atherogenic autoantigen: oxidized LDL complexes with beta2-glycoprotein I. (2003) (31)
Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus (2019) (30)
Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: A systematic review. (2017) (30)
Prevalence and clinical significance of subungual splinter haemorrhages in patients with the antiphospholipid syndrome. (1995) (30)
New Tests to Detect Antiphospholipid Antibodies: Antiprothrombin (aPT) and Anti-Phosphatidylserine/Prothrombin (aPS/PT) Antibodies (2014) (29)
Immunological findings in Kawasaki disease: an evaluation in a cohort of Italian children. (1997) (29)
Strain differences in binding properties of estrogen receptors in immature and adult BALB/c and MRL/MP-lpr/lpr mice, a model of systemic lupus erythematosus. (2000) (29)
The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients (2012) (29)
Management of hypogammaglobulinaemia occurring in patients with systemic lupus erythematosus. (2008) (29)
Migraine in Hughes syndrome--heparin as a therapeutic trial? (2001) (29)
Hughes syndrome crosses boundaries. (2002) (29)
Association of Thrombotic Microangiopathy and Intimal Hyperplasia With Bleeding Post–Renal Biopsy in Antiphospholipid Antibody–Positive Patients (2014) (29)
[Adaptation and validation of the Spanish version of a disease-specific quality of life measure in patients with systemic lupus erythematosus: the Lupus quality of life]. (2010) (29)
Management of antiphospholipid syndrome. (2009) (29)
Antiphospholipid antibodies and the endothelium (2000) (29)
Autoantibodies in systemic lupus erythematosus and urticarial vasculitis. (1995) (28)
American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort (2014) (28)
Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies. (2002) (28)
Treatment of pregnancy loss in Hughes syndrome: a critical update. (2002) (28)
Allergic disorders in systemic vasculitis: a case-controlled study. (1994) (28)
Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant? (2000) (28)
Polymorphic light eruption and the HLA DRB1*0301 extended haplotype are independent risk factors for cutaneous lupus erythematosus (2001) (28)
Fcγ Receptor IIA H/R131 Polymorphism in Patients with Antiphospholipid Antibodies (1998) (27)
Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome (2012) (27)
The anti-phospholipid antibody syndrome (Hughes syndrome): therapeutic aspects. (2000) (27)
Antiphospholipid (Hughes) Syndrome (2004) (26)
Evidence for sexual dimorphism of estrogen receptors in hypothalamus and thymus of neonatal and immature Wistar rats. (1999) (26)
The Antiphospholipid Syndrome (1996) (26)
Heparin and osteoporosis during pregnancy: 2002 update (2002) (26)
Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus (2019) (26)
Lymphocyte activation markers and von Willebrand factor antigen in Wegener's granulomatosis: potential markers for disease activity. (1999) (25)
Minocycline-induced arthritis. (1998) (25)
Improved monitoring of clinical response in Systemic Lupus Erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1 (2016) (24)
Systemic lupus erythematosus (2001) (23)
AUTOIMMUNITY, PART A: BASIC PRINCIPLES AND NEW DIAGNOSTIC TOOLS (2007) (23)
Hypertension as the presenting feature of the antiphospholipid syndrome (2002) (23)
Antiendothelial cell antibodies in inflammatory myopathies: distribution among clinical and serologic groups and association with interstitial lung disease. (2000) (23)
Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients. (2014) (23)
Development of systemic lupus erythematosus after chemotherapy and radiotherapy for malignant thymoma. (1995) (23)
Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus. (1992) (23)
Managing lupus patients during pregnancy. (2009) (23)
Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. (2008) (22)
Syndrome X and Hughes syndrome (2002) (22)
Antibodies Against Platelet-Activating Factor in Patients with Antiphospholipid Antibodies (1994) (22)
Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus (2006) (22)
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. (2020) (22)
Antibodies to beta2-glycoprotein I: a potential marker for clinical features of antiphospholipid antibody syndrome in patients with systemic lupus erythematosus. (1998) (22)
Systemic lupus erythematosus and antiphospholipid syndrome during pregnancy: maternal and fetal complications and their management. (2000) (22)
Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index (2020) (21)
Development of the Asia Pacific Lupus Collaboration cohort (2018) (21)
Effects of β2‐glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions (2002) (21)
Prevalence of an abnormal ankle-brachial index in patients with antiphospholipid syndrome with pregnancy loss but without thrombosis: a controlled study (2006) (21)
The treatment of antiphospholipid syndrome: a harmonic contrast. (2007) (21)
Antiphospholipid syndrome: an update (2015) (21)
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort (2021) (20)
Antiferritin antibodies discovered by phage display expression cloning are associated with radiographic damage in rheumatoid arthritis. (2005) (20)
Non-infective verrucous endocarditis in a patient with 'primary' antiphospholipid syndrome. (1991) (20)
Estrogen and progesterone receptors in murine models of systemic lupus erythematosus. (2001) (20)
Diagnosis of antiphospholipid syndrome (2005) (20)
Correlation between beta2-glycoprotein I valine/leucine247 polymorphism and anti-beta2-glycoprotein I antibodies in patients with primary antiphospholipid syndrome. (1999) (20)
Is it time for biosimilars in autoimmune diseases? (2013) (20)
Increased cutaneous reactions to hydroxychloroquine (Plaquenil) possibly associated with formulation change: comment on the letter by Alarcón. (2002) (20)
Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol (2005) (19)
Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy. (2003) (19)
Antibodies to Endothelial Cells and Vascular Damage (1993) (19)
IL-2, IL-6 and TNF levels in primary antiphospholipid syndrome. (1992) (19)
Tissue factor in antiphospholipid syndrome: shifting the focus from coagulation to endothelium. (2003) (19)
Targeted therapy in antiphospholipid syndrome (2014) (18)
Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies? (2016) (18)
Antiphospholipid antibody syndrome. (1994) (18)
Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach (2018) (18)
Drugs Targeting B-Cells in Autoimmune Diseases (2014) (18)
Epidemiology of systemic lupus erythematosus at the change of the millennium: lessons from the Euro-Lupus and the LUMINA projects (2006) (18)
Therapeutic advances in systemic lupus erythematosus. (1998) (17)
Lack of association between antiphospholipid antibody and WHO classification in lupus nephritis. (2001) (17)
Low-dose pulse cyclophosphamide in the treatment of neuropsychiatric lupus (2003) (17)
Polymyositis-dermatomyositis: a clinical review. (1989) (17)
Antiphospholipid antibodies in homozygous sickle cell disease. (1992) (17)
Infective endocarditis, rheumatoid factor, and anticardiolipin antibodies. (1990) (17)
Management of the antiphospholipid syndrome. (1991) (17)
Antiphospholipid antibodies cross-reacting with erythrocyte membranes. A case report. (1992) (16)
Seventy years after Hench’s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus (2020) (16)
Hughes syndrome : antiphospholipid syndrome (2000) (16)
6 Antiphospholipid syndrome in SLE (1998) (16)
Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. (2021) (16)
Prevalence & clinical associations of anticardiolipin antibodies in patients with systemic lupus erythematosus in India. (1990) (15)
The DWEYS peptide in systemic lupus erythematosus. (2012) (15)
Rheumatological complications of beta-thalassaemia: an overview. (2018) (15)
‘Seronegative antiphospholipid syndrome’: an update (2019) (15)
Inhibition of chronic relapsing experimental allergic encephalomyelitis in the mouse by the alkyl-lysophospholipid ET-18-OCH3. (1991) (15)
Routine repeated echocardiographic monitoring of fetuses exposed to maternal anti-SSA antibodies: time to question the dogma (2019) (15)
Therapy of systemic lupus erythematosus: new agents and new evidence (2000) (15)
Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome. (2019) (15)
IgG2 restriction of anti-beta2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: comment on the article by Sammaritano et al. (1998) (15)
Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort (2018) (14)
‘A new dawn of anticoagulation for patients with antiphospholipid syndrome?’ (2012) (14)
THU0628 IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES. BIG DATA ANALYSIS OF 13,051 CASES (IMMUNOCANCER INTERNATIONAL REGISTRY) (2019) (14)
Distribution of Two Common Idiotypes of Anticardiolipin Antibodies in Sera of Patients with Primary Antiphospholipid Syndrome, Systemic Lupus Erythematosus and Monoclonal Gammopathies (1992) (14)
Impaired estrogen priming of progesterone receptors in uterus of MRL/MP-lpr/lpr mice, a model of systemic lupus erythematosus (SLE). (2000) (14)
Natural immune response involving anti-endothelial cell antibodies in normal and lupus pregnancy. (2000) (14)
Systemic Lupus Erythematosus in Males: Analysis of Clinical and Laboratory Features (1992) (14)
Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria? (2017) (14)
Lack of association of antibodies to ribosomal P proteins with lupus membranous glomerulonephritis: comment on the article by Do Nascimento et al. (2006) (14)
Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome. (2007) (14)
SYSTEMIC LUPUS ERYTHEMATOSUS AND RELATED SYNDROMES (1992) (14)
Effects of oestradiol and the oestrogen antagonist Ici 182,780 on the delayed type hypersensitivity (DTH) index and on serum levels of IgM and IgG in ovariectomised Balb/C and MRL/Mp-Lpr/Lpr mice, a model of systemic lupus erythematosus (SLE). (2001) (13)
The ANCA test: its clinical relevance. (1990) (13)
Complement factor 2 deficiency: a clinical and serological family study. (1992) (13)
Most anticardiolipin antibodies in mixed connective tissue disease are beta2-glycoprotein independent. (1998) (13)
Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort (2019) (13)
'Overlap' syndromes. (1990) (13)
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach (2020) (13)
Antiphospholipid antibodies and risk for recurrent vascular events. (2004) (13)
Hypertension and the antiphospholipid antibodies. (1993) (13)
A normal ECG at birth does not exclude significant congenital cardiac conduction disease associated with maternal anti-Ro antibodies. (2001) (13)
Musculoskeletal manifestations of the antiphospholipid syndrome (2016) (12)
The BILAG-2004 systems tally—a novel way of representing the BILAG-2004 index scores longitudinally (2012) (12)
Antiphospholipid antibodies do not a syndrome make (2002) (12)
ANTIPHOSPHOLIPID ANTIBODIES AND THROMBOSIS (1988) (12)
Antiphospholipid syndrome: a consensus for treatment? (2003) (12)
Management of the Hughes syndrome. (1996) (12)
Antiphospholipid syndrome in SLE. (1998) (12)
Current status and future prospects for the treatment of antiphospholipid syndrome (2016) (11)
Treatment of mesenteric angina with prolonged anticoagulation in a patient with antiphospholipid (Hughes) syndrome and coeliac artery stenosis (2006) (11)
Systemic lupus erythematosus in pregnancy (2004) (11)
Antiphospholipid antibodies--middle aged but robust. (1994) (11)
An evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of arterial thrombosis in patients with the antiphospholipid syndrome. (2000) (11)
Oxidized low-density lipoprotein as a risk factor of thrombosis in antiphospholipid syndrome (2003) (11)
Sneddon's syndrome (1989) (10)
Advances in antiphospholipid (Hughes') syndrome. (1998) (10)
Safety and efficacy of fluconazole treatment for Candida oesophagitis in AIDS. (1991) (10)
Multiple sclerosis and the antiphospholipid (Hughes) syndrome: a common differential diagnosis? (2004) (10)
[Antiphospholipid syndrome in obstetrics]. (2012) (10)
Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort (2020) (10)
Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. (2021) (10)
Possible mechanisms of action of the antiphospholipid binding antibodies. (1989) (10)
Specificity of estrogen receptors in rat thymus. (1993) (10)
Chromium-51 ethylenediamine tetraacetic acid glomerular filtration rate: a better predictor than glomerular filtration rate calculated by the Cockcroft-Gault formula for renal involvement in systemic lupus erythematosus patients. (2001) (10)
Systemic lupus erythematosus - Reply (2001) (10)
[Antiendothelial cell antibodies]. (1990) (9)
GAPSS: the Global Anti-Phospholipid Syndrome Score RHEUMATOLOGY (2013) (9)
Duration of Anticoagulation Treatment for Thrombosis in APS: Is It Ever Safe to Stop? (2013) (9)
Goldblatt's kidney, Hughes syndrome and hypertension (2002) (9)
A Comparison of 2019 EULAR/ACR SLE Classification Criteria with Two Sets of Earlier SLE Classification Criteria. (2020) (9)
Antiphospholipid antibodies, valvular heart disease and systemic lupus erythematosus. (1989) (9)
N2010 adult-onset Still's disease complicated by hemophagocytic syndrome and catastrophic antiphospholipid syndrome resulting in four limb amputation. (2013) (9)
Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria (2021) (9)
Postpartum spontaneous colonic perforation due to antiphospholipid syndrome. (2009) (9)
Autoimmune diseases : acute and complex situations (2011) (8)
Recurrent atraumatic metatarsal, rib and sacral insufficiency fractures in a woman with the antiphospholipid syndrome (2013) (8)
Phospholipid Autoantibodies — Cardiolipin (1996) (8)
Cancer risk in a large inception SLE cohort: Effects of demographics, smoking, and medications. (2020) (8)
Mycophenolate mofetil: A potential treatment for reducing proteinuria associated with membranous lupus nephritis. (2003) (8)
Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. (2018) (8)
Arterial stenosis in antiphospholipid syndrome: Update on the unrevealed mechanisms of an endothelial disease. (2018) (8)
Pregnancy outcomes in mixed connective tissue disease: a multicentre study. (2019) (8)
Genetics of antiendothelial cell antibodies in systemic lupus erythematosus: the role of HLA-DP alleles. (1992) (8)
[B-cell-depletion therapy in systemic autoinmune diseases. Recommendations for use in clinical practice]. (2011) (7)
Thrombocytopenia in the antiphospholipid syndrome. (1997) (7)
Anticardiolipin test and the antiphospholipid (Hughes) syndrome: 20 years and counting! (2004) (7)
O58. Longterm Outcomes of Children Born to Mothers with SLE Exposed to Hydroxychloroquine in Pregnancy (2014) (7)
Prevalence of hypertension in 600 patients with antiphospholipid syndrome. (2003) (7)
[Anti-endothelial cell antibodies in systemic lupus erythematosus: association with vascular and renal lesions]. (1992) (7)
Circulating oxidized LDL forms complexes with β2-glycoprotein I Published, JLR Papers in Press, January 16, 2003. DOI 10.1194/jlr.M200329-JLR200 (2003) (7)
RAPS: a prospective randomised controlled phase II/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE (2013) (7)
Antibodies against endothelial cells in patients with multiple sclerosis (1996) (7)
Practical management of pregnancy in systemic lupus erythematosus (1993) (7)
Heart Disease, Pregnancy and Systemic Autoimmune Diseases (2007) (7)
Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. (2019) (7)
[Treatment of systemic lupus erythematosus: myths, certainties and doubts]. (2013) (6)
Fluctuation of anti-endothelial cell antibody titers in " mixed connective tissue disease. (2012) (6)
Lupus, thrombotic thrombocytopenic purpura, and antiphospholipid antibodies (1989) (6)
139 – Antiphospholipid syndrome: Overview of pathogenesis, diagnosis, and management (2015) (6)
Detection of brain-reactive autoantibodies in the sera of patients with systemic lupus erythematosus and cerebral involvement. (1995) (6)
Is there a role for phospholipases in the anti-cardiolipin syndrome? (1988) (6)
Anti-PL4 antibody in SLE. (1998) (6)
Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index (2020) (6)
European Working Party on Systemic Lupus Erythematosus: a 10 year report (2001) (6)
Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions. (2002) (6)
Polymyositis complicating D-penicillamine treatment. (1991) (6)
The association of pure red cell aplasia with the antiphospholipid syndrome (2001) (6)
Aspirin to treat obstetric manifestations of the antiphospholipid syndrome. (2001) (6)
Clinical significance of anti-beta 2-glycoprotein I antibodies. (1996) (5)
Rivaroxaban Limits Complement Activation Compared to Warfarin in Antiphospholipid Syndrome Patients with Venous Thromboembolism (2015) (5)
[Orthopedic manifestations of the antiphospholipid syndrome]. (2007) (5)
Cerebral embolism complicating Libman-Sacks endocarditis--full recovery using recombinant tissue plasminogen activator. (2002) (5)
Multiple small-vessel occlusions in systemic lupus erythematosus. (1989) (5)
Double blind, crossover, randomised trial comparing low molecular weight heparin versus placebo in the treatment of chronic headache (2003) (5)
[Pregnancy in systemic autoimmune diseases: Myths, certainties and doubts]. (2016) (5)
The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus (2013) (5)
Longitudinal analysis of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in antiphospholipid syndrome and in healthy pregnancy. (2003) (5)
Markers of vascular damage in lupus pregnancy. (1997) (4)
Antiphospholipid antibodies: which and when? (1990) (4)
[Diagnosis of antiphospholipid syndrome: From an historical perspective to the emergence of new autoantibodies]. (2016) (4)
THU0649 PHENOTYPIC CLUSTERS OF RHEUMATIC/SYSTEMIC IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES (IMMUNOCANCER INTERNATIONAL REGISTRY) (2019) (4)
Correlation between b 2-glycoprotein I valine / leucine 247 polymorphism and anti- b 2-glycoprotein I antibodies in patients with primary antiphospholipid syndrome (1999) (4)
Antiphospholipid antibodies and valve disease in patients with systemic lupus erythematosus. (1993) (4)
Manifestations osseuses du syndrome des antiphospholipides (2007) (4)
The clinical aspects of the antiphospholipid syndrome (2004) (4)
Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment (2017) (4)
Antiendothelial cell antibodies (AECA) in systemic lupus erythematosus (SLE) (1997) (4)
Antiphospholipid Syndrome Handbook (2010) (3)
Antiphospholipid Syndrome and Atherosclerosis (2001) (3)
Psychiatric disorders in patients with systemic lupus erythematosus: lack of association with antiphospholipid antibodies. (1993) (3)
Clinical significance of anti-β2-glycoprotein I antibodies (1996) (3)
How I treat How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome : a case-based review (2007) (3)
Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications (2021) (3)
[Avascular necrosis of the bone and systemic lupus erythematosus]. (1987) (3)
Prevalence of headache and relationship with the presence of antiphospholipid antibodies in systemic lupus erythematosus (2000) (3)
Antiphospholipid antibodies in a Brazilian population with systemic lupus erythematosus. (1989) (3)
Echocardiography and digital subtraction angiography in detection of mycotic false aneurysm complicating coarctation of the aorta. (1988) (3)
Antiphospholipid antibodies hasten atheroma (1996) (3)
Anticoagulation for venous thromboembolism. (1999) (3)
Rheumatic diseases and pregnancy: a national survey about practice patterns among rheumatologists and obstetricians. (2018) (3)
A new role for antimalarials in systemic lupus erythematosus treatment (2010) (3)
Anticardiolipin Antibodies in Isolated Retinal Vasculitis (1993) (3)
Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset (2021) (3)
Prolactin, the immune response and lupus. (1999) (3)
Anti-Ro and Lymphopenia in SLE (1993) (3)
Antiphospholipid syndrome: treatment controversies (2006) (3)
Oral Abstracts 1: Connective Tissue DiseaseO1. Long-Term Outcomes of Children Born to Mothers with SLE (2013) (3)
Seronegative antiphospholipid syndrome. Author's reply (2004) (3)
The use of laboratory methods in differential diagnosis and treatment of SLE and antiphospholipid syndrome (2007) (3)
Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now? (2020) (2)
Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria? (2016) (2)
The prevalence of an abnormal ankle-brachial index in primary Antiphospholipid Syndrome. (2003) (2)
262 Longitudinal Assessment of Systemic Lupus Erythematosus Disease Activity: British Isles Lupus Assessment Group 2004, Systemic Lupus Erythematosus Disease Activity Index 2000 or Both? (2016) (2)
B-cell-depleting Therapy in Systemic Lupus (2012) (2)
Lupus and pregnancy in the 21st century (2014) (2)
[Secondary prevention of esophageal candidiasis with fluconazole in acquired immunodeficiency syndrome]. (1992) (2)
The importance of antiphospholipid antibodies. (1990) (2)
Raps (rivaroxaban in antiphospholipid syndrome): a prospective randomised controlled phase II/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE (2015) (2)
Managing Lupus Nephritis in Pregnant Women: Comment on the Article by Hahn et al (2013) (2)
[Anti-phospholipid antibodies]. (1988) (2)
OP0299-PARE Attitudes of Patients and Physicians in the Treatment of Rheumatological Disease During Pregnancy (2015) (2)
Hughes Syndrome: Highways and Byways (2013) (2)
an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. (2016) (2)
Connective tissue disease: Trial of SLE therapies in real-world settings (2012) (2)
[Treatment of esophageal candidiasis with fluconazole in acquired immunodeficiency syndrome. Comparative study of 2 therapeutic schemes]. (1992) (2)
AB0487 Antiphospholipid Syndrome and Epilepsy: Where Do We Stand? (2016) (2)
Antiphospholipid syndrome. (1999) (2)
Chapter 27 – Cardiopulmonary Disease in SLE (2013) (2)
Outcome in patients with anticardiolipin antibodies: A prospective 4 years follow-up (2000) (2)
Management of APS (2010) (2)
Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine (2022) (2)
Anticardiolipin antibody. (1989) (2)
Rivaroxaban limits complement activation in patients with thrombotic antiphospholipid syndrome (2015) (2)
Antiphosphatidylserine/Prothrombin Antibodies in Systemic Lupus Erythematosus (2013) (1)
Cerebrovascular disease in the Hughes/antiphospholipid syndrome (APS) (2000) (1)
Anti-Dense Fine Speckled 70 Autoantibodies in Systemic Lupus 1 The Prevalence and Determinants of Anti-DFS 70 Autoantibodies in an International Inception Cohort of Systemic Lupus Erythematosus Patients Running Head : Anti-Dense Fine Speckled 70 Autoantibodies in SLE 1 (2018) (1)
Hughes Syndrome: A Short History of Antiphospholipid Syndrome (1999) (1)
Unusual Clinical Manifestations of the Antiphospholipid Syndrome (2006) (1)
Handbook of Systemic Autoimmune Diseases (2016) (1)
Hughes Syndrome (2000) (1)
Thromboprophylaxis with low molecular weight heparin during pregnancy (1994) (1)
Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome (2012) (1)
Antibodies to beta2-glycoprotein I (1998) (1)
prospective study of 1,000 patients syndrome during a 5-year period: a multicenter Morbidity and mortality in the antiphospholipid (2009) (1)
Eular On-line Course on Rheumatic Diseases - module n°19 (2008) (1)
Revisiting antiphospholipid antibodies (2004) (1)
Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study (2017) (1)
Antiphospholipid antibodies, thrombosis and vasculitis. Proceedings of a symposium. London, 16th December 1988. (1989) (1)
O15. Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multi-Centre Register (2015) (1)
Rituximab in SLE (2012) (1)
Anticardiolipin antibodies in isolated retinal vasculitis. (1994) (1)
123. A Systematic Analysis of the Safety of Prescribing Anti-Rheumatic Immunosuppressive and Biologic Drugs in Pregnant Women with Inflammatory Arthritis (2014) (1)
Seronegative antiphospholipid syndrome - Reply (2004) (1)
Treatment of antiphospholipid antibody syndrome (2010) (1)
[Hughes syndrome: anticardiolipin or antiphospholipid]. (1995) (1)
Renal artery stenosis in hypertensive patients with antiphosphotipid syndrome: The effects of anticoagulation. (2003) (1)
Antiphospholipid (Hughes) syndrome - Preface (2001) (1)
THU0561 Clinical practice guideline for diagnosis and management of catastrophic antiphospholipid syndrome (2017) (1)
Diagnosis of antiphospholipid syndrome (2008) (1)
[Determination of beta-2-microglobulin levels in patients with systemic lupus erythematosus: correlation with clinical and biological parameters]. (1987) (1)
Sneddon's syndrome and primary anti‐phospholipid syndrome (PAPS) (1990) (1)
FRI0093 A Systematic Analysis of the Safety of Prescribing of Anti-Rheumatic, Immunosuppressive and Biologic Drugs in Men Trying to Conceive (2013) (1)
Protein S, C4b-binding protein (C4BP) and beta 2-glycoprotein I (??2-GPI) binding interaction: Inhibition by human monoclonal anticardiolipin antibody (Mo-aCL) (1995) (1)
Pregnancy in systemic autoimmune diseases: Myths, certainties and doubts (2016) (1)
Comparison of responsiveness of BILAG-2004, SLEDAI-2000 and BILAG Systems Tally (BST). (2021) (1)
Irrational testing for antiphospholipid antibodies (2013) (1)
[Hughes syndrome and thrombosis: the debate goes on]. (2002) (1)
Antiphospholipid antibodies and cardiovascular disease (1993) (1)
[Neurological manifestations of the antiphospholipid syndrome]. (2005) (1)
AB0504 CLINICOPATHOLOGICAL CHARACTERISTICS AS POSSIBLE PREDICTOR OF RENAL OUTCOME IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS FOLLOWING THE INDUCTION OF REMISSION PHASE (2019) (1)
The effect of anti-Ro antibody of the fetus in the absence of overt congenital complete heart (2002) (1)
Advances in Lupus and Sjögren's Syndrome (2007) (1)
The Endovascular Compartment (1998) (1)
B Cell Depletion therapy and Pregnancy Outcome in Severe Refractory Autoimmune Disease (2011) (0)
Immunemediated mechanism forthrombosis: antiphospholipid antibody binding toplatelet membranes* (1988) (0)
Anticardiolipin antibodies and cardiovascular disease. (1996) (0)
Chapter 14 – Global Antiphospholipid Syndrome Score (2017) (0)
Hughes syndrome: 'sticky blood'. (2009) (0)
Detection andimportance ofanticardiolipin antibodies (1993) (0)
The role of antiaggregant and anticoagulant therapy in the treatment of headache in systemic lupus erythematosus (2000) (0)
Mormed Project: A New 21st Century Web Platform for Multilingual Communication in systemic Lupus Erythematosus and Antiphospholipid Syndrome (2012) (0)
Syndrome des antiphospholipides et grossesse (2012) (0)
Antiphosphatidylserine/Prothrombin Antibodies in Systemic Lupus (2014) (0)
A pioneer in clinical diagnostics (2007) (0)
Book Review: Publishing your medical research paper. What they don't teach you in Medical School Byrne DW (1999) (0)
The Cost of Management of Adult Active Systemic Lupus Erythematosus in the UK. (2012) (0)
Tests for Hughes Syndrome (2013) (0)
SP0153 Lessons from aps trials (2017) (0)
Chapter 17 Treatment of Late Pregnancy Complications in the Antiphospholipid Syndrome (2009) (0)
of Rheumatology ' ' Non-criteria ' ' Antiphospholipid Antibodies Closing the Serological Gap in the Antiphospholipid Syndrome : The Value of (2017) (0)
Iconography : Manifestations osseuses du syndrome des antiphospholipides (2007) (0)
Chapter 15 Treatment of Thrombosis in the Antiphospholipid Syndrome (2009) (0)
Clinical presentation of antiphospholipid syndrome (2021) (0)
Anti-c1q autoantibodies as a predictor of lupus nephritis. (2003) (0)
The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus (2015) (0)
Unmonitored low molecular weight heparin (Dalteparin) in high-risk pregnancies (2000) (0)
[Trichomegaly: an exceptional expression of the acquired immunodeficiency syndrome]. (1989) (0)
O21 BILAG2004-Pregnancy index is sensitive to change (2018) (0)
Neuropsychiatric manifestations in the antiphospholipid (Hughes) syndrome (2004) (0)
Clinical Studies Examining Thrombosis Related to Autoimmune Antiphospholipid Antibodies~!2009-09-20~!2009-09-25~!2010-03-11~! (2010) (0)
Mortality, Morbidity, and Damage Associated with aPL (2010) (0)
CE-10 Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort (2016) (0)
Apolipoprotein(a) deposition in atherosclerotic coronary arteries of a patient with systemic lupus erythematosus: comment on the article by Romero et al - Reply (2000) (0)
treatment 10 in the pathogenesis of the disease and effects of coenzyme Q Mitochondrial dysfunction in antiphospholipid syndrome: implications (2014) (0)
801 Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk (2021) (0)
The BILAG2004-pregnancy index for assessment of SLE disease activity in pregnancy is sensitive to change (2008) (0)
Other Biological Therapies in Primary Sjögren’s Syndrome (2011) (0)
Treatment of antiphospholipid syndrome (2021) (0)
Anti-vimentin/cardiolipin antibodies in “seronegative” Antiphospholipid syndrome (2010) (0)
Comprar Autoimmune Diseases | Khamashta, Munther A. | 9780857293572 | Springer (2011) (0)
The BILAG2004-pregnancy index has construct and criterion validity (2008) (0)
Basic science232. Certolizumab pegol prevents pro-inflammatory alterations in endothelial cell function (2012) (0)
Impaired trophoblast invasion in antiphospholipid syndrome pregnancies: Longitudinal analysis of insulin-like growth factor-I and Insulinlike growth factor binding protein-1. (2002) (0)
Intestinal Behçet's Disease (2017) (0)
Diagnosis and Classification (2019) (0)
Membranous lupus nephritis: An update. (2003) (0)
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS) RHEUMATOLOGY (2014) (0)
BILAG-2004 index: A reliable tool for assessment of SLE activity (2005) (0)
Autoimmune and connective tissue disorders (2012) (0)
Liver and Gastrointestinal Tract (2013) (0)
39 Management of Thrombosis in the Antiphospholipid Syndrome (2000) (0)
“Endotheliology” in Antiphospholipid Antibodies (2001) (0)
Preliminary Rasch analysis of SLEDAI-2000 index: An ordinal scale index with internal construct validity (2006) (0)
Patient care pathways for pregnancy in rare and complex rheumatic diseases: results from an international survey. (2023) (0)
matomyositis: aclinical review (1989) (0)
Case reports 1. IGG4 Related Fibrosis: A Treatable Disease. Four Cases in a District General Hospital (2011) (0)
Comparison of thalidomide toxicity profiles in treatment of Lupus and myeloma: Efficacy and toxicity are not dose dependent. (2002) (0)
[Diabetic cheirarthropathy simulating sclerodermia]. (1990) (0)
Reproductive issues in rheumatology: do you know how to advise your patients?I1. Is pregnancy a stress test for subsequent development of autoimmunity? (2012) (0)
Antiphospholipid antibodies and HLA associations in primary S jogren ' s syndrome (0)
Sifalimumab Slows Disease Activity in SLE (2014) (0)
Correction of Previews 200100168381. Absence of conduction defects in the electrocardiograms of mothers with children with congenital complete heart block. Correction of title.) (2001) (0)
Antiphosphollpid antibodies in sickle cell disease (1994) (0)
What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome? (2022) (0)
THU0013 Longterm Outcomes of Children Born to Mothers with SLE Exposed to Azathioprine in Pregnancy (2014) (0)
The BILAG-2004 index is associated with development of new damage in SLE. (2022) (0)
C URRENT OPINION Targeted therapy in antiphospholipid syndrome (2014) (0)
Antiphospholipid antibodies inhomozygous sickle cell disease (1992) (0)
Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally (2022) (0)
Late pregnancy complications in systemic lupus erythematosus and antiphospholipid syndrome. (1997) (0)
Arteries and Veins (2013) (0)
OP0086 Eular Recommendations for Women's Health and the Management of Family Planning, Assisted Reproduction, Pregnancy, and Menopause in Patients With Systemic Lupus Erythematosus and/or the Antiphospholipid Syndrome (2015) (0)
Kawasaki syndrome: the Florentine experience (1996) (0)
Chapter 16 - Treatment of Thrombosis in Antiphospholipid Syndrome (2017) (0)
OP0120 A Systematic Analysis of the Safety of Prescribing Anti-Rheumatic Immunosuppressive and Biologic Drugs in Pregnant Women with Inflammatory Arthritis (2014) (0)
Book Review: Systemic Lupus Erythematosus. Third edition. Robert G Lahita (Ed) (1999) (0)
311 INFLAMMATION, LEUKOCYTE ACTIVATION, AND SURROGATE ATHEROSCLEROSIS MARKERS IN RHEUMATOID ARTHRITIS PATIENTS ARE RELATED TO MITOCHONDRIAL DEPOLARISATION AND OXIDATIVE STRESS (2011) (0)
INCREASED RATE OF LUPUS FLARE DURING PREGNANCY AND THE PUERPERIUM : A PROSPECTIVE STUDY OF 78 PREGNANCIES (1996) (0)
OP0252 NEUROPATHIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INTERNATIONAL, INCEPTION COHORT STUDY (2019) (0)
[Systemic autoimmune diseases during pregnancy: a practical approach]. (1998) (0)
92 – ANTICARDIOLIPIN ANTIBODIES (2007) (0)
CT-03 Anifrolumab reduces disease activity in multiple organ domains in patients with moderate to severe systemic lupus erythematosus (2016) (0)
Systemic Lupus Erythematosus: Indirect B-Cell Blocking (2014) (0)
CE-21 The prevalence and determinants of ANTI-DFS70 antibodies in an international inception cohort of systemic lupus erythematosus (SLE) patients (2016) (0)
Premature cardiovascular disease in SLE: A study from a tertiary referral centre. (2003) (0)
126 Cross sectional validation of BILAG2004-Pregnancy Index (2018) (0)
Incorrect Values for Intractable and Cluster Headaches at Enrollment Shown in Figure 1 and Incorrect Prevalence of Headache at Ten Years in Text of the Article by Hanly et al (Arthritis Rheum, November 2013) (2014) (0)
BSR AND BHPR ORAL PRESENTATION OF ABSTRACTS CONNECTIVE TISSUE DISEASES (2015) (0)
THU0635 Pregnancy outcomes in mixed connective tissue disease: results from a multicentre cohort study (2018) (0)
risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome (0)
SLE and antiphospholipid syndrome 168. Dyslipidaemia, Hyperhomocysteinaemia and Antiphospholipid Antibodies as Risk Factors of Thrombotic Complications in Patients with Systemic Lupus Erythematosus (2011) (0)
Protein Z gene polymorphisms in systemic lupus erythematosus (2008) (0)
version of SELENA comparison of BILAG 2004 and the flare with systemic lupus erythematosus : a An assessment of disease flare in patients (0)
Anti-c1q in lupus nephritis: Strong correlation between titres and renal disease activity. (2003) (0)
14th International Congress on Antiphospholipid Antibodies - APLA & 4th LACA - Latin American Congress on Autoimmunity (2013) (0)
I70 Development of Evidence-Based Recommendations for Diagnosis, Assessment and Treatment of Lupus (2016) (0)
BHPR: Audit and Clinical Evaluation103. Dental Health in Children and Young Adults with Inflammatory Arthritis: Access to Dental Care (2013) (0)
Pregnancy ingranulomatous vasculitis (1995) (0)
AB0839 The efficacy and safety of denosumab local experience) (2017) (0)
Targeting B Cells in Other Systemic Autoimmune Diseases (2014) (0)
A SYSTEMATIC ANALYSIS OF THE SAFETY OF PRESCRIBING OF ANTI-RHEUMATIC, IMMUNOSUPPRESSIVE AND BIOLOGIC DRUGS IN PREGNANT WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASE (2013) (0)
Treatment of Pregnancy Complications in Antiphospholipid Syndrome (2017) (0)
Birmingham Construction of a frailty index as a novel health measure in systemic lupus erythematosus (2019) (0)
Intensity and duration of oral anticoagulation in antiphospholipid antibody associated thrombosis. (2002) (0)
Hematological Immune Cytopenias and Anti-Phospholipid Antibodies (2020) (0)
RHEUMATIC DISEASES Leader The ANCA test : its clinical relevance (0)
Complement deficiency in systemic lupus erythematosus (2003) (0)
[Thrombocytopenia, pregnancy and systemic lupus erythematosus]. (1987) (0)
Running Head : Economic Evaluation of Lupus Damage in an International Inception Cohort Title : Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach (2019) (0)
CS-07 Economic evaluation of damage accrual in an international SLE inception cohort (2018) (0)
Low frequency of IgA anticardiolipin antibody in patients with systemic lupus erythematosus (2000) (0)
Antiprothrombin antibodies: Detection, immunological characteristics and clinical significance in patients with systemic lupus erythematosus. (2002) (0)
[Lipoproteins and atherosclerosis in systemic lupus erythematosus]. (1992) (0)
CE-22 Cancer in systemic lupus erythematosus: results from the slicc inception cohort (2016) (0)
Multiple microinfarcts in the Hughes/antiphospholipid syndrome (APS) (2000) (0)
Plasma levels of TNF alpha are increased in patients with the antiphospholipid syndrome (2000) (0)
[Acute cerebral organic syndrome, systemic lupus erythematosus and antiphospholipid antibodies]. (1989) (0)
[Role of platelet phospholipases in the antiphospholipid antibody syndrome]. (1988) (0)
Classification Criteria for APS (2010) (0)
Systemic lupus erythematosus (2001) (0)
Length of gestation in systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS): Survival analysis of 282 pregnancies in 152 women. (2002) (0)
205 Correlation of Soluble Vascular Cell Adhesion Molecule 1 with B Cell Activation and Plasma Cells in Systemic Lupus Erythematosus (2016) (0)
414 OXIDATIVE STRESS MEDIATES APL-INDUCED THROMBOSIS AND ATHEROSCLEROSIS DEVELOPMENT IN ANTIPHOSPHOLIPID SYNDROME (2011) (0)
Comments on the Editorial “Antiphospholypid Syndrome: New Clinical and Therapeutic Perspectives” (2007) (0)
Differences Between Primary and Secondary APS (2010) (0)
40 – THE CLINICAL ASPECTS OF THE ANTIPHOSPHOLIPID SYNDROME (2004) (0)
Outcome of 35 treated pregnancies in women with primary antiphospholipid syndrome. (2002) (0)
aPL and Transplantation (2010) (0)
Systemic Lupus Erythematosus, Antiphospholid Syndrome, Scleroderma, and Inflammatory Myopathies (2001) (0)
Delay in recognising other causes contribute to fetal loss in women with antiphospholipid antibodies (2000) (0)
Antiphospholipid antibodies in sickle cell disease. (1994) (0)
Lupus comes of age. (1992) (0)
The Sixth International Lupus Conference, Barcelona 24–28 March 2001 (2001) (0)
Systemic lupus erythematosus in50year olds (1992) (0)
Neuropsychiatric lupus: Relevance of Antiphospholipid antibodies. (2002) (0)
Chapter 87 – Anticardiolipin Antibodies (2014) (0)
Complicated Pregnancies in Patients with Autoimmune Systemic Diseases (2011) (0)
Complement factor 2 deficiency: serological family study (2004) (0)
Chapter 13 Endocrine Manifestations of the Antiphospholipid Syndrome (2008) (0)
BILAG-2004 captures SLE disease activity better than SLEDAI-2000 (2005) (0)
inapatient withlupus anticoagulant andthrombosis (1989) (0)
Antiprothrombin antibodies in infections and antiphospholipid syndrome (2000) (0)
Hypertension in primary antiphospholipid syndrome. (2003) (0)
Chapter 47 – Treatment of Antiphospholipid Syndrome (2007) (0)
322. Patients with Refractory Systemic Lupus Erythematosus Requiring Biologic Therapy Have Significant Levels of Baseline Co-Morbidities: Results from a National Multi-Centre Register (2014) (0)
Patients with learning disability in the community (1999) (0)
ELISA using Thrombofax is useful to verify antiphospholipid antibodies. (1990) (0)
[Sneddon syndrome and antiphospholipid antibodies]. (1988) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Munther A. Khamashta?

Munther A. Khamashta is affiliated with the following schools:

King's College London

Munther A. Khamashta's Academic­Influence.com Rankings

Munther A. Khamashta's Degrees

Why Is Munther A. Khamashta Influential?

Munther A. Khamashta's Published Works

Published Works

What Schools Are Affiliated With Munther A. Khamashta?

Munther A. Khamashta's AcademicInfluence.com Rankings